Covid19, Diabetes Mellitus
Conditions
Brief summary
DM2 is a major comorbidity of COVID-19. It has been observed that subjects with DM2 require more medical interventions, have a significantly higher mortality (7.8% versus 2.7%) and injuries of multiple organs that the individuals not diabetics. In situations of glycemic variability, phenomena of oxidative stress and activation of protein kinase C can be initiated , through the release of pro-inflammatory cytosines , which could induce microvascular damage .Patients with diabetes and COVID-19 were shown to be more likely to develop serious or critical illness with more complications, and to have higher incidence rates of antibiotic therapy, non-invasive and invasive mechanical ventilation, and death (11.1% vs. 4.1%).
Interventions
None listed
Sponsors
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
No
Inclusion criteria
* Confirmed COVID-19 pneumonia * Diabetes mellitus
Exclusion criteria
* Less than 3 days of hospital care
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Glucose variability | For up to two weeks, during hospitalization | Percentage of time within the ADA recommended range |
| Insulin use | For up two weeks, during hospitalization | Average daily UI of insulin per patient |
Countries
Mexico
Contacts
Primary ContactALFONSO GULIAS HERRERO
Backup ContactALHELY GAYTAN SANTILLAN
Outcome results
None listed